Evaluation effects of treatment with IL-6R inhibitor on clinical response and biomarkers in patients with rheumatoid arthritis (RA) not responding to DMARDs and/or a first biological agent. [Valutazione degli effetti del trattamento con un inibitore dell'IL-6R sulla risposta clinica e sui biomarcatori in pazienti con artrite reumatoide (AR) non responsiva ai DMARDs e/o al primo biologico]
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- 18 Apr 2013 Planned end date changed from 5 May 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov
- 18 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01835613).
- 23 Jan 2013 New trial record